U.S. Regenerative Medicine Legislation Map
Hover a state · click for bills & detail⚖︎ Federal layer · U.S. Congress
What Washington is doing — the ceiling every state law sits under
The Ron Johnson Right to Try 2.0 bill is the one to watch: a federal pathway for individualized, one-patient cell therapies that can't run a Phase I trial.
Open & authorized states are direct-to-physician markets today — where Made Regen products can be administered under state authority now.
Advancing states are the pipeline — seed distributor and clinician relationships before the law lands, not after.
Federal Right to Try 2.0 would open individualized, one-patient cell therapies nationwide — a direct fit for autologous manufacturing.
All jurisdictions (—)
Click any row to open its legislation record. Sort by column.
| State | Openness tier | Bills | Enacted | Progression |
|---|